top of page

NCT02002598 : Phase 1 /2 -Carfilzomib + Bendamustine and Dex in New MM

  • Writer: Completed
    Completed
  • Dec 6, 2013
  • 1 min read

Updated: Mar 28, 2022


ree

This study is designed to define dose-limiting toxicity and determine preliminary evidence of efficacy of Carfilzomib (CFZ) in combination with bendamustine and dexamethasone for patients with newly diagnosed multiple myeloma (MM).


Columbia University


ClinicalTrials.gov Identifier: NCT02002598





Blood Cancer J : Feb 3, 2020

PMID: 32015343


Posts Archive
bottom of page